AI Article Synopsis
- Modern vaccines often rely on adjuvants, like aluminum compounds, to boost immune responses but have drawbacks such as persistence and side effects.
- New research highlights mesoporous silica (MS) as a promising alternative, particularly when doped with calcium, magnesium, and zinc, which enhances its effectiveness.
- These modified MS nanospheres have shown increased degradation rates and a strong ability to stimulate anticancer immune responses, indicating their potential as clinical immunoadjuvants for cancer therapies.
Article Abstract
Modern vaccines usually require accompanying adjuvants to increase the immune response to antigens. Aluminum (alum) compounds are the most commonly used adjuvants in human vaccinations for infection diseases. However, alum adjuvants are nondegradable, cause side effects due to the persistence of alum at injection sites, and are rather ineffective for cancer immunotherapy, which requires the Th1 immune response. Recently, we have shown that a plain mesoporous silica (MS) adjuvant can stimulate Th1 anticancer immunity for cancer vaccines. Herein, MS nanospheres doped with Ca, Mg, and Zn (MS-Ca, MS-Mg, and MS-Zn) showed significantly higher degradation rates than pure MS. Moreover, MS-Ca, MS-Mg, and MS-Zn nanospheres stimulated anticancer immune response and increased the CD4 and CD8 T cell populations in spleen. The MS-Ca, MS-Mg, and MS-Zn nanospheres with improved biodegradability and excellent ability to induce Th1 anticancer immunity show potential for clinical applications as cancer immunoadjuvants.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1021/acsami.7b16118 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!